Seaside Therapeutics, Roche deal

Roche said it declined to exercise its option to license STX209 from Seaside for autism. Earlier this month, Seaside reported that the compound missed the primary endpoint in the Phase IIb Study 209AS208 to treat autism spectrum disorders (ASD). Roche had received the option for the oral selective GABA B receptor agonist last year as part of a deal to develop disease modifying treatments for fragile X syndrome and ASD (see BioCentury, June 25, 2012 & May 6, 2013). ...